Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ASCO 2023
ASCO 2023
AstraZeneca's drug combo shows positive results in late-stage cancer trial
Reuters
Fri, 05/26/23 - 10:09 am
ASCO 2023
AstraZeneca
Imfinzi
Lynparza
endometrial cancer
ASCO: BMS pitches Breyanzi as the first CAR-T for CLL. But will a single-arm trial persuade the FDA?
Fierce Pharma
Fri, 05/26/23 - 09:57 am
ASCO 2023
Bristol Myers Squibb
Breyanzi
CAR-T
CLL
SLL
clinical trials
ASCO puts spotlight on advancing antibody-drug conjugate pipeline
BioPharma Dive
Thu, 05/25/23 - 08:51 pm
ASCO 2023
antibody-drug conjugate
Merck
BioNTech
Daiichi Sankyo
ASCO: Regeneron's Opdualag rival records double the historical response rate in melanoma
Fierce Biotech
Thu, 05/25/23 - 08:49 pm
ASCO 2023
Regeneron
advanced melanoma
fianlimab
ASCO: Merck gives final look at Keytruda study in first-line cervical cancer. Will FDA change its mind?
Fierce Pharma
Thu, 05/25/23 - 08:37 pm
ASCO 2023
Merck
Keytruda
cervical cancer
ASCO preview: Merck's Keytruda, Novartis' Kisqali face their moment of truth in early-stage cancers
Fierce Pharma
Thu, 05/25/23 - 08:33 pm
ASCO 2023
Merck
Keytruda
Novartis
Kisqali
non-small cell lung cancer
early breast cancer
Pages
« first
‹ previous
1
2